Spruce Biosciences, Inc.(SPRB)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

SPRB Spruce Biosciences, Inc.

已收盘 06-01 16:00:00 EDT

50.70

-0.57

-1.11%

盘后50.02

-0.68-1.34%

19:33 EDT

最高53.08	最低50.00	成交量3.12万
今开50.92	昨收51.27	日振幅6.00%
总市值1.40亿	流通市值1.35亿	总股本275.23万
成交额160.07万	换手率1.18%	流通股本265.34万
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

{"stockData":{"symbol":"SPRB","market":"US","secType":"STK","nameCN":"Spruce Biosciences, Inc.","latestPrice":50.7,"timestamp":1780344000000,"preClose":51.27,"halted":0,"volume":31190,"hourTrading":{"tag":"盘后","latestPrice":50.02,"preClose":50.7,"latestTime":"19:33 EDT","volume":269,"amount":13472.26,"timestamp":1780356826101,"change":-0.68,"changeRate":-0.013412,"amplitude":0.013412},"delay":0,"changeRate":-0.011117612638970162,"floatShares":2653399,"shares":2752300,"eps":-38.620026,"marketStatus":"已收盘","change":-0.57,"latestTime":"06-01 16:00:00 EDT","open":50.92,"high":53.0811,"low":50.0049,"amount":1600713.62387,"amplitude":0.06,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-38.620026,"tradingStatus":0,"nextMarketStatus":{"tag":"盘前交易","tradingStatus":1,"beginTime":1780387200000},"marketStatusCode":5,"adr":0,"listingDate":1602216000000,"exchange":"NASDAQ","adjPreClose":51.27,"preHourTrading":{"tag":"盘前","latestPrice":51.28,"preClose":51.27,"latestTime":"09:00 EDT","volume":57,"amount":2943.030099,"timestamp":1780318827728,"change":0.01,"changeRate":0.000195,"amplitude":0.014238},"postHourTrading":{"tag":"盘后","latestPrice":50.02,"preClose":50.7,"latestTime":"19:33 EDT","volume":269,"amount":13472.26,"timestamp":1780356826101,"change":-0.68,"changeRate":-0.013412,"amplitude":0.013412},"volumeRatio":0.607914,"impliedVol":0.883,"impliedVolPercentile":0.9787},"requestUrl":"/m/hq/s/SPRB","defaultTab":"news","newsList":[{"id":"1128975868","title":"Spruce Biosciences任命Brian Walls为市场准入副总裁、Darren Johnson为商业运营副总裁，进一步强化商业领导团队","url":"https://stock-news.laohu8.com/highlight/detail?id=1128975868","media":"美股速递","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1128975868?lang=zh_cn&edition=full","pubTime":"2026-05-04 20:02","pubTimestamp":1777896164,"startTime":"0","endTime":"0","summary":"Spruce Biosciences宣布两项重要高管任命：Brian Walls出任市场准入副总裁，Darren Johnson担任商业运营副总裁。此次人事布局将显著增强公司的商业领导团队实力。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SPRB","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1175629000","title":"Spruce Biosciences与Kaken所有授权协议终止，未获里程碑款项及特许权使用费","url":"https://stock-news.laohu8.com/highlight/detail?id=1175629000","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1175629000?lang=zh_cn&edition=full","pubTime":"2026-03-21 05:11","pubTimestamp":1774041100,"startTime":"0","endTime":"0","summary":"Spruce Biosciences, Inc.宣布，公司与Kaken Pharmaceutical Co., Ltd.先前签订的所有许可协议及相应权利均将终止。根据协议条款，此次终止不会产生任何未实现的里程碑付款或特许权使用费。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","SPRB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1153012960","title":"Spruce Biosciences与Kaken制药合作协定将于2026年3月31日终止","url":"https://stock-news.laohu8.com/highlight/detail?id=1153012960","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1153012960?lang=zh_cn&edition=full","pubTime":"2026-03-21 05:09","pubTimestamp":1774040952,"startTime":"0","endTime":"0","summary":"根据最新提交至美国证券交易委员会的文件显示，生物制药公司Spruce Biosciences, Inc.与日本Kaken制药株式会社签署的合作协议，将于2026年3月31日正式终止。该协议涉及双方在特定治疗领域的研发协作，终止决定经双方协商一致达成。合作协议终止后，双方将按照协议条款完成剩余工作交接与知识产权归属安排。此次合作终止不会对Spruce Biosciences现有核心业务造成重大影响，公司将继续推进其他在研管线的发展。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","SPRB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1102000150","title":"Spruce Biosciences Inc 与 Jefferies Llc 于2026年3月9日签订公开市场销售协议 - 美国证券交易委员会文件","url":"https://stock-news.laohu8.com/highlight/detail?id=1102000150","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1102000150?lang=zh_cn&edition=full","pubTime":"2026-03-09 19:25","pubTimestamp":1773055517,"startTime":"0","endTime":"0","summary":"Spruce Biosciences Inc 已与 Jefferies Llc 达成一项公开市场销售协议，该协议于2026年3月9日签署，相关细节已在美国证券交易委员会（SEC）的公开文件中披露。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SPRB","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1155598503","title":"Spruce Biosciences公司依据销售协议可发售普通股至最高计划额度——美国证监会文件披露","url":"https://stock-news.laohu8.com/highlight/detail?id=1155598503","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1155598503?lang=zh_cn&edition=full","pubTime":"2026-03-09 19:25","pubTimestamp":1773055516,"startTime":"0","endTime":"0","summary":"根据提交至美国证券交易委员会（SEC）的最新文件显示，生物制药企业Spruce Biosciences, Inc. 已获得授权，可依据现行销售协议，提供并出售其普通股，总规模最高可达计划规定的上限金额。\n该安排为公司提供了灵活的融资渠道，使其能够根据市场状况和资金需求，适时在公开市场进行股票发售。此次备案明确了公司未来可能进行的股权融资活动，但具体发售时间、数量及价格将视实际情况而定。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SPRB","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1199432746","title":"Spruce Biosciences, Inc. 预计现金及等价物可支撑运营至2027年初","url":"https://stock-news.laohu8.com/highlight/detail?id=1199432746","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1199432746?lang=zh_cn&edition=full","pubTime":"2026-03-09 19:12","pubTimestamp":1773054742,"startTime":"0","endTime":"0","summary":"生物制药企业Spruce Biosciences, Inc. 近日宣布，公司现有现金及现金等价物预计足以支持当前运营计划持续至2027年初。这一资金规划为公司在儿科内分泌疾病治疗领域的临床研发工作提供了稳定的财务保障。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SPRB","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1192644043","title":"Spruce Biosciences公司针对B型Sanfilippo综合征（MPS IIIB）的TA-ERT疗法BLA申请计划于2026年第四季度提交","url":"https://stock-news.laohu8.com/highlight/detail?id=1192644043","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1192644043?lang=zh_cn&edition=full","pubTime":"2026-03-09 19:11","pubTimestamp":1773054675,"startTime":"0","endTime":"0","summary":"Spruce Biosciences公司宣布，其针对B型Sanfilippo综合征（MPS IIIB）的TA-ERT疗法的生物制品许可申请（BLA）提交计划正稳步推进，预计将于2026年第四季度完成。这一关键里程碑的达成，标志着公司在罕见病治疗领域取得了重要进展。TA-ERT疗法作为一种创新的治疗策略，旨在为患有这种严重遗传性疾病的患者提供新的希望。公司对按计划实现这一目标充满信心，并持续致力于推动该疗法的研发进程。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SPRB","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1145719204","title":"罕见病商业化领域资深领袖Dale Hooks加入Spruce Biosciences，担任首席商务官","url":"https://stock-news.laohu8.com/highlight/detail?id=1145719204","media":"美股速递","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1145719204?lang=zh_cn&edition=full","pubTime":"2026-03-09 19:04","pubTimestamp":1773054291,"startTime":"0","endTime":"0","summary":"Spruce Biosciences, Inc.近日宣布，已正式任命在罕见病商业化领域拥有卓越成就的Dale Hooks为公司首席商务官。这一重要人事变动将进一步加强公司在罕见病治疗领域的商业化战略布局与执行能力。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SPRB","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2614725490","title":"Spruce Biosciences, Inc.股价上涨11.98% 市值涨269.69万美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2614725490","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2614725490?lang=zh_cn&edition=full","pubTime":"2026-02-24 22:57","pubTimestamp":1771945072,"startTime":"0","endTime":"0","summary":"北京时间2026年02月24日22时57分，Spruce Biosciences, Inc.股票出现波动，股价大幅拉升11.98%。Spruce Biosciences, Inc.股票所在的生物技术行业中，整体涨幅为0.37%。Spruce Biosciences, Inc.公司简介：Spruce Biosciences Inc 是一家后期生物制药公司，专注于开发和商业化针对未满足医疗需求的罕见内分泌疾病的新疗法。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202602242257529541d5e4&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202602242257529541d5e4&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["SPRB","SPRBD","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1135613257","title":"Spruce Biosciences股价飙升8.16%，公司推进罕见儿童脑部疾病药物向FDA提交申请","url":"https://stock-news.laohu8.com/highlight/detail?id=1135613257","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1135613257?lang=zh_cn&edition=full","pubTime":"2026-02-18 22:35","pubTimestamp":1771425349,"startTime":"0","endTime":"0","summary":"Spruce Biosciences, Inc.股价录得显著上涨，单日涨幅达8.16%。此次股价波动源于公司宣布其针对罕见儿童脑部疾病治疗的药物研发取得关键进展，正式迈向向美国食品药品监督管理局（FDA）提交申请的阶段。\n这一里程碑事件激发了市场对该公司未来商业化前景的积极预期，投资者信心得到提振。该药物的目标适应症为一种罕见的儿童脑部疾病，若最终获得FDA批准，将有望填补该治疗领域的空白。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","SPRB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1196247101","title":"Spruce Biosciences与美国FDA就治疗B型圣菲利波综合征药物TA-ERT举行B类会议取得积极进展","url":"https://stock-news.laohu8.com/highlight/detail?id=1196247101","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1196247101?lang=zh_cn&edition=full","pubTime":"2026-02-18 20:03","pubTimestamp":1771416230,"startTime":"0","endTime":"0","summary":"Spruce Biosciences公司近日宣布，其针对B型圣菲利波综合征（又称MPS IIIB）的候选药物TA-ERT，在与美国食品药品监督管理局（FDA）举行的B类会议上获得了积极反馈。此次会议重点讨论了该药物的临床开发计划，双方就后续试验方案达成重要共识，为推进TA-ERT的研发进程奠定了坚实基础。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","SPRB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2608362407","title":"Spruce Biosciences, Inc.盘中异动 股价大涨5.14%报82.00美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2608362407","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2608362407?lang=zh_cn&edition=full","pubTime":"2026-02-04 04:47","pubTimestamp":1770151670,"startTime":"0","endTime":"0","summary":"北京时间2026年02月04日04时47分，Spruce Biosciences, Inc.股票出现波动，股价大幅拉升5.14%。截至发稿，该股报82.00美元/股，成交量2.6059万股，换手率2.43%，振幅3.83%。Spruce Biosciences, Inc.股票所在的生物技术行业中，整体涨幅为0.14%。Spruce Biosciences, Inc.公司简介：Spruce Biosciences Inc 是一家后期生物制药公司，专注于开发和商业化针对未满足医疗需求的罕见内分泌疾病的新疗法。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260204044750a478c38e&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260204044750a478c38e&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","SPRBD","SPRB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1175232475","title":"重新发布-Spruce Biosciences, Inc. : H.c. Wainwright 宣布覆盖，给予买入评级和目标价220美元（澄清为宣布覆盖）","url":"https://stock-news.laohu8.com/highlight/detail?id=1175232475","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1175232475?lang=zh_cn&edition=full","pubTime":"2025-12-22 19:25","pubTimestamp":1766402745,"startTime":"0","endTime":"0","summary":"重新发布-Spruce Biosciences, Inc. : H.c. Wainwright 宣布覆盖，给予买入评级和目标价220美元（澄清为宣布覆盖）","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SPRB","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1137422413","title":"Spruce Biosciences, Inc.：H.c. Wainwright启动覆盖并给予买入评级，目标价为220美元","url":"https://stock-news.laohu8.com/highlight/detail?id=1137422413","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1137422413?lang=zh_cn&edition=full","pubTime":"2025-12-22 19:10","pubTimestamp":1766401812,"startTime":"0","endTime":"0","summary":"Spruce Biosciences, Inc.：H.c. Wainwright启动覆盖并给予买入评级，目标价为220美元","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SPRB","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1153345003","title":"Spruce Biosciences任命资深制药商业领袖Keli Walbert为董事会成员","url":"https://stock-news.laohu8.com/highlight/detail?id=1153345003","media":"美股速递","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1153345003?lang=zh_cn&edition=full","pubTime":"2025-12-15 21:01","pubTimestamp":1765803688,"startTime":"0","endTime":"0","summary":"Spruce Biosciences任命资深制药商业领袖Keli Walbert为董事会成员","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SPRB","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1189875027","title":"Spruce Biosciences股价在盘前上涨2.6%，因Leerink Partners将评级从“市场表现”上调至“跑赢大盘”","url":"https://stock-news.laohu8.com/highlight/detail?id=1189875027","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1189875027?lang=zh_cn&edition=full","pubTime":"2025-12-03 19:26","pubTimestamp":1764761177,"startTime":"0","endTime":"0","summary":"Spruce Biosciences股价在盘前上涨2.6%，此前Leerink Partners将其评级从“市场表现”上调至“跑赢大盘”。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","SPRB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2516632349","title":"Spruce Biosciences, Inc.盘中异动 大幅下挫9.23%报0.353美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2516632349","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2516632349?lang=zh_cn&edition=full","pubTime":"2025-03-03 22:32","pubTimestamp":1741012321,"startTime":"0","endTime":"0","summary":"北京时间2025年03月03日22时32分，Spruce Biosciences, Inc.股票出现异动，股价大幅跳水9.23%。Spruce Biosciences, Inc.股票所在的生物技术行业中，整体涨幅为0.21%。其相关个股中，Entero Therapeutics Inc.、Alto Neuroscience, Inc.、Geovax Labs, Inc.涨幅较大，Allarity Therapeutics, Inc.、Entero Therapeutics Inc.、Aeon Biopharma, Inc.较为活跃，换手率分别为47.26%、26.91%、22.55%，振幅较大的相关个股有Entero Therapeutics Inc.、Spruce Biosciences, Inc.、Cibus, Inc.，振幅分别为21.22%、19.25%、9.55%。Spruce Biosciences, Inc.公司简介：Spruce Biosciences Inc 是一家后期生物制药公司，专注于开发和商业化针对未满足医疗需求的罕见内分泌疾病的新疗法。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250303223201abe63345&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250303223201abe63345&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["SPRB","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2514378974","title":"Spruce Biosciences, Inc.盘中异动 早盘股价大涨6.13%报0.405美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2514378974","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2514378974?lang=zh_cn&edition=full","pubTime":"2025-02-28 22:33","pubTimestamp":1740753182,"startTime":"0","endTime":"0","summary":"北京时间2025年02月28日22时33分，Spruce Biosciences, Inc.股票出现波动，股价急速上涨6.13%。截至发稿，该股报0.405美元/股，成交量1.7316万股，换手率0.04%，振幅6.62%。Spruce Biosciences, Inc.股票所在的生物技术行业中，整体跌幅为0.12%。Spruce Biosciences, Inc.公司简介：Spruce Biosciences Inc 是一家后期生物制药公司，专注于开发和商业化针对未满足医疗需求的罕见内分泌疾病的新疗法。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250228223302abe0eaf0&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250228223302abe0eaf0&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["SPRB","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2513773326","title":"Spruce Biosciences, Inc.盘中异动 股价大跌5.12%报0.399美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2513773326","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2513773326?lang=zh_cn&edition=full","pubTime":"2025-02-24 23:08","pubTimestamp":1740409726,"startTime":"0","endTime":"0","summary":"北京时间2025年02月24日23时08分，Spruce Biosciences, Inc.股票出现异动，股价快速下挫5.12%。截至发稿，该股报0.399美元/股，成交量9.7834万股，换手率0.24%，振幅3.95%。Spruce Biosciences, Inc.股票所在的生物技术行业中，整体涨幅为0.64%。Spruce Biosciences, Inc.公司简介：Spruce Biosciences Inc 是一家后期生物制药公司，专注于开发和商业化针对未满足医疗需求的罕见内分泌疾病的新疗法。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250224230847abdb16f7&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250224230847abdb16f7&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","SPRB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2513961772","title":"Spruce Biosciences, Inc.盘中异动 早盘股价大跌5.67%报0.401美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2513961772","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2513961772?lang=zh_cn&edition=full","pubTime":"2025-02-21 22:31","pubTimestamp":1740148295,"startTime":"0","endTime":"0","summary":"北京时间2025年02月21日22时31分，Spruce Biosciences, Inc.股票出现异动，股价大幅下挫5.67%。截至发稿，该股报0.401美元/股，成交量1.7247万股，换手率0.04%，振幅0.00%。Spruce Biosciences, Inc.股票所在的生物技术行业中，整体涨幅为0.33%。Spruce Biosciences, Inc.公司简介：Spruce Biosciences Inc 是一家后期生物制药公司，专注于开发和商业化针对未满足医疗需求的罕见内分泌疾病的新疗法。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250221223136a24eb02f&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250221223136a24eb02f&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["SPRB","BK4139"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.sprucebiosciences.com","stockEarnings":[{"period":"1week","weight":0.0038},{"period":"1month","weight":-0.0765},{"period":"3month","weight":-0.0668},{"period":"6month","weight":-0.4873},{"period":"1year","weight":736.6978},{"period":"ytd","weight":-0.4114}],"compareEarnings":[{"period":"1week","weight":0.0145},{"period":"1month","weight":0.0631},{"period":"3month","weight":0.1028},{"period":"6month","weight":0.107},{"period":"1year","weight":0.2821},{"period":"ytd","weight":0.1093}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Spruce Biosciences, Inc.最初于2014年11月在特拉华州成立为一家有限责任公司。该公司是一家处于后期阶段的生物制药公司，专注于开发和商业化治疗罕见的内分泌疾病的新疗法，这些疾病的医疗需求尚未得到满足。该公司正在初步开发全资候选产品tildacerfont，作为潜在的第一个非甾体疗法，为患有典型先天性肾上腺增生症的患者提供显著改善的疾病控制和减少类固醇负担。","yearOnYearQuotes":[{"month":1,"riseRate":0.333333,"avgChangeRate":0.190445},{"month":2,"riseRate":0.5,"avgChangeRate":-0.036118},{"month":3,"riseRate":0.166667,"avgChangeRate":-0.209049},{"month":4,"riseRate":0,"avgChangeRate":-0.19428},{"month":5,"riseRate":0.333333,"avgChangeRate":-0.048966},{"month":6,"riseRate":0.4,"avgChangeRate":-0.079875},{"month":7,"riseRate":0.6,"avgChangeRate":0.089441},{"month":8,"riseRate":0.4,"avgChangeRate":0.028537},{"month":9,"riseRate":0.4,"avgChangeRate":-0.136102},{"month":10,"riseRate":0.4,"avgChangeRate":2.105377},{"month":11,"riseRate":0.5,"avgChangeRate":0.001192},{"month":12,"riseRate":0.333333,"avgChangeRate":0.217863}],"exchange":"NASDAQ","name":"Spruce Biosciences, Inc.","nameEN":"Spruce Biosciences, Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.42.3","shortVersion":"4.42.3","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Spruce Biosciences, Inc.(SPRB)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供Spruce Biosciences, Inc.(SPRB)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"Spruce Biosciences, Inc.,SPRB,Spruce Biosciences, Inc.股票,Spruce Biosciences, Inc.股票老虎,Spruce Biosciences, Inc.股票老虎国际,Spruce Biosciences, Inc.行情,Spruce Biosciences, Inc.股票行情,Spruce Biosciences, Inc.股价,Spruce Biosciences, Inc.股市,Spruce Biosciences, Inc.股票价格,Spruce Biosciences, Inc.股票交易,Spruce Biosciences, Inc.股票购买,Spruce Biosciences, Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Spruce Biosciences, Inc.(SPRB)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供Spruce Biosciences, Inc.(SPRB)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}